ResMed completed its $340 million acquisition of Noctrix Health on June 1, bringing the FDA De Novo-classified Nidra Tonic Motor Activation therapy for restless legs syndrome into its portfolio. First revealed on ResMed’s fiscal third-quarter earnings call in April, the deal makes Noctrix a wholly owned subsidiary. The Nidra device delivers noninvasive stimulation of the peroneal nerves to relieve moderate-to-severe restless legs syndrome symptoms in adults who have not responded to medication. ResMed plans to fold the technology into its connected devices and digital health line, describing restless legs syndrome as the third most common sleep disorder after insomnia and obstructive sleep apnea. The transaction also marks the first exit for Angelini Ventures, which took part in Noctrix’s $40 million Series C financing in 2024.
ResMed’s move is a clear expansion beyond its longtime focus on CPAP systems and ventilators, into neuromodulation and digital therapeutic territory. Absorbing Noctrix’s wearable gives the company a nonpharmacologic alternative in a therapeutic space often left hanging between underperforming drugs and fragmented care. By linking Nidra to its digital ecosystem, ResMed revives a strategy similar to its 2018 Propeller Health purchase, collecting patient data, improving feedback loops, and, in effect, building loyalty through integration rather than hardware alone. It’s an efficient way to make the portfolio feel modern again.
For investors, the acquisition reinforces a broader pattern: ResMed defending its position in home-based sleep care by diversifying, not merely refreshing existing products. If integration accelerates as planned, the company can use its provider network to move Nidra into clinical pathways quickly, creating recurring revenue from devices and digital services. Whether restless legs therapy reaches the scale of obstructive sleep apnea is still unclear; the data are encouraging, though not yet deep. But if adoption among sleep physicians builds momentum, this deal might quietly reset how ResMed owns the insomnia-to-CPAP continuum. Some may see it as incremental. I’d call it a smart hedge against stagnation. For ongoing analysis of drug-free sleep treatments, see RxInfo.ai.
